SELECT PUBLICATIONS

Chang JC et al. Induction of apoptosis without change in cell proliferation in primary breast cancers with neoadjuvant trastuzumab. San Antonio Breast Cancer Symposium 2003;Abstract 24.

Geyer CE Jr. et al. Cardiac safety analysis of the first stage of NSABP B-31, a randomized trial comparing the safety and efficacy of Adriamycin and cyclophosphamide (AC) followed by Taxol to that of AC followed by Taxol plus Herceptin in patients (Pts) with operable, node-positive (N+), HER-2 overexpressing breast cancer (HER2+BC). San Antonio Breast Cancer Symposium 2003;Abstract 23.

HERA Study Team. Trastuzumab (H: Herceptin) following adjuvant chemotherapy (CT) significantly improves disease-free survival (DFS) in early breast cancer (BC) with HER2 overexpression: The HERA Trial. San Antonio Breast Cancer Symposium 2005;Abstract 11.

Joensuu H et al; FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354(8):809-20. Abstract

Joensuu H et al. Trastuzumab in combination with docetaxel or vinorelbine as adjuvant treatment of breast cancer: The FinHer Trial. San Antonio Breast Cancer Symposium 2005;Abstract 2.

Muss HB et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330(18):1260-6. Abstract

Perez EA et al. NCCTG N9831. May 2005 Update. Presentation. ASCO 2005;Abstract 556.

Piccart-Gebhart MJ. First results of the HERA trial. Presentation. ASCO 2005a. No abstract available

Piccart-Gebhart MJ et al; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER 2-positive breast cancer. N Engl J Med 2005b;353(16):1659- 72. Abstract

Press MF et al. Topoisomerase II-alpha gene amplification as a predictor of responsiveness to anthracycline containing chemotherapy in the Cancer International Research Group 006 clinical trial of trastuzumab (Herceptin) in the adjuvant setting. San Antonio Breast Cancer Symposium 2005;Abstract 1045.

Romond EH et al. Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer — Combined analysis of NSABP-B31/NCCTG-N9831. Presentation. ASCO 2005a. No abstract available

Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER 2 positive breast cancer. N Engl J Med 2005b;353(16):1673-84. Abstract

Slamon D et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 1.

Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 2001;28(1 Suppl 3):13-9. Abstract

Vogel CL et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20(3):719-26. Abstract